SUNNYVALE, Calif., Feb. 1, 2023
/PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today
the appointment of Robert C. Kill to
the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled
healthcare executive with more than 30 years' experience
transforming various healthcare-related companies.
In his most recent executive position as CEO of Parata Systems,
Mr. Kill grew company revenue over 5X during his tenure before it
sold last year for more than $1.5
billion. Before Parata, Mr. Kill was affiliated with two
private equity funds, Frazier Healthcare Partners and Altamont
Capital Partners, where he focused on various health care portfolio
companies. Prior to this, Mr. Kill held executive leadership
positions with medical device, healthcare service and healthcare IT
companies. He began his career at Baxter Healthcare.
"Rob's public and private company CEO experiences directly align
with our organization's strategic focus areas, making him an
excellent addition to the Accuray Board of Directors. He has a
well-established reputation for driving transformative business
results, improving customers' experience and managing key
stakeholder relationships on behalf of both large and small
companies. We are very excited to have Rob join our board and look
forward to his contributions," said Suzanne
Winter, President and CEO of Accuray.
"As a healthcare industry veteran, I understand the value that
the Accuray radiation therapy technology provides to medical care
teams and patients, and I strongly believe there is untapped
potential here. I'm looking forward to working with Suzanne, the
senior management team and other board members to help create value
for all of Accuray's constituents," said Rob Kill.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn,
Twitter, and YouTube.
Investor
Contact
|
Media
Contact
|
Aman
Patel,CFA
|
Beth Kaplan
|
Investor Relations,
ICR-Westwicke
|
Accuray
|
+1 (443)
450-4191
|
+1 (408)
789-4426
|
amanpatel@westwicke.com
|
bkaplan@accuray.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/robert-c-kill-joins-accuray-board-of-directors-301735852.html
SOURCE Accuray Incorporated